Author:
Balabko Ljubov,Andreev Katerina,Burmann Nadine,Schubert Melanie,Mathews Martina,Trufa Denis I.,Reppert Sarah,Rau Tilmann,Schicht Martin,Sirbu Horia,Hartmann Arndt,Finotto Susetta
Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Aberle, D. R. et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med 369, 920–931, 10.1056/NEJMoa1208962 (2013).
2. Maus, M. K. et al. KRAS mutations in non-small-cell lung cancer and colorectal cancer: Implications for EGFR-targeted therapies. Lung cancer, 10.1016/j.lungcan.2013.11.010 (2013).
3. Kang, H. J. et al. Comparison of clinical characteristics between patients with ALK-positive and EGFR-positive lung adenocarcinoma. Respir Med, 10.1016/j.rmed.2013.11.020 (2013).
4. Song, L., Rawal, B., Nemeth, J. A. & Haura, E. B. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling. MCT 10, 481–494, 10.1158/1535-7163.MCT-10-0502 (2011).
5. Andreev, K., Graser, A., Maier, A., Mousset, S. & Finotto, S. Therapeutical measures to control airway tolerance in asthma and lung cancer. Front Immunol 3, 216, 10.3389/fimmu.2012.00216 (2012).
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献